Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InMed Pharmaceuticals ( (INM) ) just unveiled an announcement.
On May 6, 2026, InMed Pharmaceuticals reported third-quarter fiscal 2026 results for the period ended March 31, 2026, highlighting new preclinical data showing its INM-901 candidate reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease. The consistent anti-inflammatory effects across in vivo, ex vivo and human organoid systems bolster confidence in INM-901’s translational potential for neuroinflammatory conditions and strengthen InMed’s positioning in Alzheimer’s drug development.
The company also disclosed that on March 4, 2026, its board approved winding down BayMedica’s commercial operations, its only revenue-generating business, which will be substantially exited by fiscal year-end June 30, 2026 while continuing limited activity during the transition. For the quarter, InMed posted a wider net loss of $3.0 million versus $2.1 million a year earlier, driven mainly by higher R&D and financing costs, reported no revenue from continuing operations, and ended March 31, 2026 with $5.2 million in cash, cash equivalents and short-term investments, down from $10.8 million at June 30, 2025.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
The score is primarily held down by weak financial quality—large continuing losses and persistent cash burn despite improving revenue/margins and low balance-sheet leverage. Technicals remain weak versus longer-term moving averages with mixed momentum signals. Corporate events add both pipeline progress and material listing/financing/regulatory risks, while valuation provides little support given unusable earnings multiple and no dividend.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a Vancouver-based pharmaceutical company listed on Nasdaq that focuses on developing a pipeline of proprietary small molecule drug candidates targeting diseases with high unmet medical needs. Its lead program, INM-901, is being advanced as a potential disease-modifying treatment for Alzheimer’s disease through modulation of neuroinflammation via CB1 and CB2 receptor signaling.
Average Trading Volume: 101,963
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.41M
For an in-depth examination of INM stock, go to TipRanks’ Overview page.